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BACKGROUND: Reactivation of the varicella zoster virus (VZV) is more common in patients with malignancies; however, the molecular
and cellular mechanisms underlying this susceptibility are unclear.
METHODS: Using ex vivo interferon-g ELISpot assays, we set out to analyse VZV-specific immune responses in a large cohort of patients
with malignancies.
RESULTS: We observed that patients with malignancies had impaired VZV-specific T-cell responses, particularly in those with
haematological malignancies and breast carcinoma. Immediate-early protein 63 (IE63)-specific T-cell responses were significantly
impaired in those with subclinical VZV re-activation.
CONCLUSIONS: Our results suggest that T-cell responses to IE63 are important in controlling VZV replication.
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Malignancy is associated with reactivation of chronic persistent
viruses such as varicella zoster virus (VZV) (Whiteside, 2006),
causing significant morbidity and mortality (Wade, 2006). Herpes
zoster is more common in patients with malignancies (Schmader,
2001; Sorensen et al, 2004) and may lead to severe disease with
multi-dermatomal involvement and visceral dissemination,
which can be lethal (Gallagher and Merigan, 1979; Onunu and
Uhunmwangho, 2004; Hackanson et al, 2005; Graue et al, 2006).
However, apart from clinically apparent VZV reactivation,
subclinical reactivation has also been reported in both immuno-
competent and immunosuppressed individuals (Schunemann et al,
1998; Quinlivan et al, 2007). Although the mechanisms underlying
such reactivation are unclear, it is thought that cell-mediated
immune responses are vital in controlling VZV replication
(Malavige et al, 2007, 2008b).
VZV glycoproteins I and E, immediate-early protein 63 (IE63)
and four specific CD4þ T cells have been shown to circulate at
persistently high frequencies in the peripheral blood of healthy
seropositive donors without a history of reactivation (Jones et al,
2006, 2007; Malavige et al, 2007, 2008a). However, VZV-specific
T-cell responses have been shown to be lower in elderly individuals
and in patients with disease such as systemic lupus erythematosus
(Miller, 1980; Levin et al, 2003; Park et al, 2004). As these groups of
individuals are at a higher risk of herpes zoster, it seems that VZV-
specific T cells are important in preventing virus reactivation.
Some important studies conducted earlier have indeed shown that
suppression of VZV-specific cellular immunity preceded the
occurrence of herpes zoster (Arvin et al, 1978, 1980). However,
with a more detailed understanding of VZV protein-specific
responses, we can now study the mechanisms that are important in
preventing virus reactivation. Therefore, we set out to analyse
the overall VZV-specific immune responses and the immune
responses to VZV IE63 and gE proteins, in a cohort of patients
with malignancies to identify the associations with viral reactivation.
MATERIALS AND METHODS
Fresh heparinised venous blood samples were obtained from 106
adult individuals with malignancies (before receiving chemo-
therapy) who were admitted to the Cancer Institute in Sri Lanka
with a past history of primary VZV infection. Samples were also
obtained from 26 patients after chemotherapy. Ethical approval for
the study was obtained from the local ethics committee.
The mean age of the donors was 49.81 years (s.d.±17.5) and 55
(51.88%) were males. The mean age at which the patients had
contracted primary VZV was 18 years (s.d.±12.67). In all, 88
patients (83.01%) had a solid malignancy (SM) and 18 (16.9%)
had a haematological malignancy (HM) (Table 1). The healthy
volunteers consisted of 19 healthy seropositive adults with a
history of primary VZV infection but no clinical reactivation.
Mean age of the seropositive donors was 34 years (range 25–62
years) with an average age of primary infection at 12.92 years
(range 2–16 years).
Ex vivo ELISpot assays were performed as previously described
(Smith et al, 2001), using freshly isolated PBMC and VZV antigen
in the form of VZV vaccine (Varilrix, GSK, Rixensart, Belgium) or
synthetic 20-mer peptides overlapping by 10 amino acids spanning
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sthe whole length of the gE or IE63 protein. PHA and FEC were
included as positive controls and the plates were incubated
overnight at 371C and 5% CO2. The ‘FEC’ peptides contain a panel
of 23, 8–11 amino acid CD8þ T-cell epitopes of Epstein–Barr
virus (EBV), Flu and CMV viruses and have been used for quality
control in ELISpot assays (Currier et al, 2002).
Quantitative real-time PCR was performed as previously
described using the ABI Prism 7700 sequence detector system
(Foster City, CA, USA) (Pevenstein et al, 1999; Quinlivan et al,
2007). Forward primers (50-CGTACACGTATTTTCAGTCCTCTTC-30)
and reverse primers (50-GGCTTAGACGTGGAGTTGACA-30)f o r
VZV ORF29 and a probe (50-(FAM)CCCGTGGAGCGCGTCGAAA
(TAMRA)-30)w e r eu s e d( P e v e n s t e i net al, 1999). The real-time
fluorescence values were measured by the quantity of a reporter dye
FAM released during amplification. The threshold limit was set in the
linear phase of exponential amplification after viewing the log-linear
view of the amplification plot.
Statistical analysis
Data analyses were carried out using GraphPad Prism 4
(San Diego, CA, USA). Data were analysed using nonparametric
tests, as frequency distribution curves showed that the data were
not normally distributed. Wilcoxon’s matched-pairs test was
used to determine the P-value in paired samples whereas the
Mann–Whitney test was used to calculate the P-values in unpaired
data. Spearman’s correlation coefficient was used to determine
the correlation and the P-value when determining correlations
between the absolute white cell count and VZV-specific T-cell
responses and absolute lymphocyte count and VZV-specific T-cell
responses.
RESULTS
Overall ex vivo T-cell responses in patients with
malignancies
We observed that overall VZV-specific T-cell responses were
significantly diminished (Po0.0001) in patients with malignancies
(mean 170.9, s.d.±244.3) when compared with healthy VZV
seropositive individuals (mean 511.3, s.d.±372.3; Figure 1).
Patients with haematological malignancies and breast cancer had
the lowest VZV-specific T-cell responses. Those with haemato-
logical malignancies had significantly lower overall T-cell
responses to VZV (as measured by responses to the VZV live
attenuated vaccine) than those with solid malignancies (Table 1;
Po0.05). However, there was no difference between the two
groups for gE or IE63 overlapping 20-mer peptides (Figure 2).
Among those with solid malignancies, patients with breast
carcinoma had significantly lower VZV-specific T-cell responses
(Po0.0001). The overall VZV-specific T-cell responses in individuals
with different malignancies are shown in Table 1. Patients with
haematological malignancies had significantly higher (Po0.05)
total white cell count (mean 11746, s.d.±9079) and significantly
higher (Po0.005) lymphocyte count (mean 3986, s.d.±3986)
than patients with solid malignancies. However, we found no
correlation with the T-cell response with either total white cell
or lymphocyte counts. We also observed no correlation between
VZV-specific T-cell responses and age of the individual or time
since occurrence of primary infection.
A significant difference was not observed between the pre- and
post-chemotherapy total white cell or lymphocyte counts in the 26
patients for whom we had post-chemotherapy samples taken at
1–2 weeks (data not shown). Furthermore, we found that there
were no significant differences in the overall VZV-specific
functional T-cell responses or for responses to gE or IE63
overlapping peptide pools in this group of patients. VZV-specific
T-cell responses also did not significantly differ between patients
on different chemotherapy regimes.
Subclinical viraemia in patients with malignancies
Of the 106 patients recruited in our study, none had clinical
evidence of VZV reactivation. However, VZV DNA was detected in
eight (7.5%) patients. The viral loads in these patients varied from
Table 1 The absolute white cell counts, the absolute lymphocyte counts and ex vivo VZV live attenuated vaccine-specific ELISpot responses in patients
with malignancies before initiation of any chemotherapy
Site of malignancy, n (%)
Absolute white cell
count (mean±s.d.)
Absolute lymphocyte
count (mean±s.d.)
T-cell responses to the live attenuated
VZV vaccine (spot forming units
per1 million PBMCs) (mean±s.d.)
Haematological, 18 (16.9) 11746±9079 10929±24737 89.72±137
Colon and rectal cancer, 13 (12.3) 6657±2499 1972±870.7 235±304.7
Ovary, 14 (13.2) 8014±3101 2353±1142 207.1±300.2
Uterus and cervix, 12 (11.3) 5414±2949 1559±538.8 172.1±346.3
Lung, 12 (11.3) 9254±3713 1837±1037 197.5±191.2
Osteosarcoma, 7 (6.6) 5786±2392 1626±1146 170.7±138.5
Breast, 7 (6.6) 9900±9787 2313±956.1 93.57±68.54
Abbreviations: PBMC¼peripheral blood mononuclear cell; VZV¼varicella zoster virus.
P<0.0001
P<0.0005 P<0.005
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Figure 1 Ex vivo IFNg ELISpot responses to VZV live attenuated vaccine,
overlapping gE 20-mer peptide pool and overlapping IE63 20-mer peptide
pools in patients with malignancies and healthy seropositive volunteers with
no evidence of VZV reactivation.
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s.d.±53.58). We observed no viral reactivation in the healthy
controls. Overall, those who had subclinical VZV reactivation had
significantly lower (Po0.01) overall VZV-specific T-cell responses
(mean 68.75, s.d.±75.9) than those with no reactivation
(mean 179.6, s.d.±251.8). Furthermore, responses to VZV IE63
overlapping 20-mer peptides were significantly lower (Po0.005)
in those with subclinical reactivation (mean 37.5, s.d.±41.9) than
in those with no reactivation (mean 105.2, s.d.±162.1). There was
no difference in T-cell responses in these two groups for VZV
gE overlapping 20-mer peptides (Figure 3).
DISCUSSION
We have shown that VZV-specific functional T-cell responses
are significantly impaired in patients with malignancies when
compared with healthy seropositive controls. These responses were
lowest in those with haematological malignancies and breast
carcinoma. It has been shown previously that patients with
colorectal carcinomas did not have any significant reduction in
CMV- and influenza-specific T-cell responses (Kiewe et al, 2009),
assessed using MHC class I tetramers. However, as detection of
antigen-specific cells by tetramers does not depend on T-cell
function, it is not clear whether the antiviral T cells of these
patients were functionally similar to healthy controls.
Subclinical VZV viraemia was observed in eight (7.5%) of the
patients. Interestingly, overall mean VZV vaccine-specific T-cell
responses, and responses to IE63 overlapping 20-mer peptides
were significantly lower in those with VZV reactivation when
compared with other patients, suggesting that IE63-specific T-cell
responses could be important in the control of VZV replication.
However, it will clearly be important to extend these findings to
other viral proteins.
We failed to see any significant differences between VZV-
specific T-cell responses in our patient cohort in both before and
after chemotherapy. However, as post-chemotherapy samples were
obtained 1–2 weeks after the initiation of chemotherapy, this
might not suffice for the occurrence of immunosuppressive effects
of the chemotherapy. Therefore, it is important to expand this
study in a larger population of patients who received chemo-
therapy and who were followed up for longer periods.
In summary, we have shown that a large cohort of patients
with malignancies had impaired T-cell responses to VZV and that
virus-specific T-cell responses were lowest in those with sub-
clinical virus reactivation. Interestingly, IE63-specific T-cell
responses were significantly impaired in those with subclinical
VZV reactivation, suggesting that T-cell responses to IE63 could be
important in controlling VZV reactivation. Furthermore, the data
suggest that enhancement of IE63-specific T-cell responses may
prove beneficial in future vaccination strategy development.
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Figure 2 Ex vivo IFNg ELISpot responses to VZV live attenuated vaccine,
overlapping gE 20-mer peptide pool and overlapping IE63 20-mer peptide
pool in patients with haematological and solid malignancies. The error bars
represent the s.e.m.
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Figure 3 Ex vivo IFNg ELISpot responses to VZV live attenuated vaccine
(VZV), overlapping gE 20-mer peptide pool and overlapping IE63 20-mer
peptide pool in patients with malignancies who had subclinical VZV
viraemia and those who were non-viraemic.
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